AbstractPurposeThe purpose of this study was to evaluate the pharmacokinetics (PK) and 24-hour analgesic effectiveness of once-daily, single-entity, extended-release hydrocodone (HYD) with abuse-deterrent properties.MethodsFour studies were included. Three open-label PK studies had the following designs: single-dose, 5-treatment, 4-period, crossover, dose-proportionality study; HYD 120 mg for 5 days (steady-state study 1); 2-treatment, 2-period, multiple-dose crossover study assessing the relative bioavailability of HYD 30 mg and hydrocodone 7.5 mg/ibuprofen 200 mg administered every 6 hours (steady-state study 2). A long-term, open-label study assessed the safety and effectiveness of HYD 20 to 120 mg in patients during a 52-week maintenanc...
Tapentadol, a Schedule II opioid with a combination of µ-opioid activity and norepinephrine reuptake...
pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during si...
Background: Evaluation of tamper resistant formulations (TRFs) and classwide Risk Evaluation and Mit...
Hydrocodone is one of the most prescribed oral analgesic drugs and it is one of the most abused drug...
Hydrocodone bitartrate is the most commonly used drug for acute and chronic pain in the U.S. with ov...
Krishna Devarakonda,1 Kenneth Kostenbader,2 Michael J Giuliani,3 Jim L Young4 1Department of Clinica...
AbstractPurposeA single-entity, once-daily, extended-release formulation of hydrocodone bitartrate (...
AbstractImmediate-release (IR) hydrocodone/acetaminophen is the most prescribed opioid in the United...
Krishna Devarakonda,1 Kenneth Kostenbader,2 Michael J Giuliani,3 Jim L Young41Department of Clinical...
AbstractIn elderly (≥75 years) individuals, age-associated physiologic changes and a higher prevalen...
Opioid abuse in the United States increased significantly over the past decade, leading to opioid-re...
BACKGROUND: Long-acting opioid formulations are advocated for maintaining pain control in chronic ca...
Background: Long-acting opioid formulations are advocated for maintaining pain control in chronic ca...
AbstractPurposeThe objective of this systematic review was to assess the clinical efficacy, safety, ...
Millions of Americans suffer from pain, which can be treated with a variety of therapies. Prescripti...
Tapentadol, a Schedule II opioid with a combination of µ-opioid activity and norepinephrine reuptake...
pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during si...
Background: Evaluation of tamper resistant formulations (TRFs) and classwide Risk Evaluation and Mit...
Hydrocodone is one of the most prescribed oral analgesic drugs and it is one of the most abused drug...
Hydrocodone bitartrate is the most commonly used drug for acute and chronic pain in the U.S. with ov...
Krishna Devarakonda,1 Kenneth Kostenbader,2 Michael J Giuliani,3 Jim L Young4 1Department of Clinica...
AbstractPurposeA single-entity, once-daily, extended-release formulation of hydrocodone bitartrate (...
AbstractImmediate-release (IR) hydrocodone/acetaminophen is the most prescribed opioid in the United...
Krishna Devarakonda,1 Kenneth Kostenbader,2 Michael J Giuliani,3 Jim L Young41Department of Clinical...
AbstractIn elderly (≥75 years) individuals, age-associated physiologic changes and a higher prevalen...
Opioid abuse in the United States increased significantly over the past decade, leading to opioid-re...
BACKGROUND: Long-acting opioid formulations are advocated for maintaining pain control in chronic ca...
Background: Long-acting opioid formulations are advocated for maintaining pain control in chronic ca...
AbstractPurposeThe objective of this systematic review was to assess the clinical efficacy, safety, ...
Millions of Americans suffer from pain, which can be treated with a variety of therapies. Prescripti...
Tapentadol, a Schedule II opioid with a combination of µ-opioid activity and norepinephrine reuptake...
pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during si...
Background: Evaluation of tamper resistant formulations (TRFs) and classwide Risk Evaluation and Mit...